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ABSTRACT  1 
Developments in microarray and high throughput sequencing (HTS) technologies 2 
have resulted in a rapid expansion of research into epigenomic changes that occur in 3 
normal development and in the progression of disease, such as cancer.  Not 4 
surprisingly, copy number variation (CNV) has a direct effect on HTS read densities 5 
and can therefore bias differential detection results.  We have developed a flexible 6 
approach called ABCD-DNA (Affinity Based Copy-number-aware Differential 7 
quantitative DNA sequencing analyses) that integrates CNV and other systematic 8 
factors directly into the differential enrichment engine. 9 
INTRODUCTION 10 
All normal cells carry the same DNA sequence, yet distinct cell types result from 11 
gene expression patterns that are controlled by a combination of genetic and 12 
epigenetic mechanisms.  In cancer, genetic and epigenetic changes result in altered 13 
gene expression patterns, such as up-regulation of oncogenes and down-regulation of 14 
tumour-suppressor genes (Stratton 2011; Jones and Baylin 2007).  Specifically, 15 
mutations in the DNA sequence or changes in copy number can alter how these genes 16 
are regulated or expressed, as can non-sequence epigenetic features, such as chemical 17 
(e.g. DNA methylation or histone modifications) or structural makeup (e.g. 18 
nucleosome occupancy).  Advances in microarray and especially HTS technologies 19 
have driven a deeper exploration of genetic and epigenetic phenomena, resulting in 20 
several large data collection projects (Stratton 2011; Jones et al. 2008; Bernstein et al. 21 
2010; International Cancer Genome Consortium 2010) as well as many smaller scale 22 
studies.  Statistical and computational tools for processing and interpreting these 23 
datasets are maturing, and altogether these give exciting prospects for the 24 
understanding, detection, prevention, and treatment of cancer and other diseases.   25 
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Recently, we highlighted that comparisons between cancer and normal epigenomes 1 
need to be informed by genomic changes (Robinson, Statham, et al. 2010; Robinson, 2 
Clare Stirzaker, et al. 2010).  Specifically, CNV has a direct effect on read densities of 3 
affinity- (or enrichment-) based assays (e.g. Chromatin immunoprecipitation, ChIP 4 
and methylated DNA capture, MBDCap); we refer to these techniques collectively as 5 
qDNA-seq, since they all provide a quantitative epigenetic readout at a specific loci. 6 
In these assays, a subset of target DNA fragments are captured, prepared, sequenced 7 
and mapped to a reference genome.  Enrichment levels are interpreted as the relative 8 
abundance across two populations having the property of interest.  Consider 9 
comparing enrichment levels between two prostate cell lines -- normal epithelial cells 10 
(PrEC) and cancer cells (LNCaP).  There is significant CNV between PrEC and 11 
LNCaP cells, as shown in Figure 1A (see also Supplementary Figure 1). The CNV 12 
imbalance leads directly to changes in read density that are not reflective of true 13 
changes in methylation (e.g. from MBDCap-seq data).  Using Illumina 14 
HumanMethylation 450k arrays as an independent assessment of changes in DNA 15 
methylation that should be unaffected by CNV (Houseman et al. 2009), Figures 1B-E 16 
highlight both false positive and false negative detections using existing algorithms; 17 
these examples are accurately detected by our ABCD-DNA approach (details below). 18 
Interestingly, because the prominent copy number state of LNCaP cells is 4 (Figure 19 
1a, Supplementary Figure 1), depth-adjusted read densities are approximately 20 
“neutral” (in terms of sampling captured DNA) when LNCaP and PrEC cells have 4 21 
and 2 copies, respectively; this further imbalance can be adjusted through 22 
“normalization” (adjustments for depth and diversity) in the statistical modeling.    23 
There are now a large number of tools for absolute analysis of qDNA-seq data;  24 
methods are available for the detection of short distinct events (e.g. MACS (Yong 25 
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Zhang et al. 2008)), enriched regions (e.g. RSEG (Qiang Song and Smith 2011), 1 
ChromaBlocks (Hawkins et al. 2010), or both simultaneously with ZINBA (Rashid et 2 
al. 2011)). However, none of the tools are designed explicitly for differential analyses 3 
or for when replication is available.  Recently, a framework called DiffBind was 4 
developed to post-process output from absolute algorithms into merged regions and 5 
perform differential analysis based on read densities (Ross-Innes et al. 2012).  6 
A separate class of methods are available to directly detect differential regions, often 7 
without the use of input or other control samples (see Table 1 for list of assays and 8 
acronyms). For example, Bock et al. detected changes in read density using Fisher’s 9 
exact test; CNV is deemed unimportant in their analysis despite no CNV-typing 10 
(Bock et al. 2010). Another strategy, ChIPDiff, assumes beta-binomially distributed 11 
tiled bin counts and uses a Hidden Markov Model (HMM) to combine adjacent 12 
differential regions (Xu et al. 2008). Similarly, RSEG scans for differential regions 13 
using an HMM with a difference-of-negative-binomials emission distribution (Qiang 14 
Song and Smith 2011). Other tools are emerging for differential analyses, such as 15 
DBChIP (Liang and Keles 2011) or by collecting existing Unix-based tools (Bardet et 16 
al. 2011), but none of these are explicitly CNV-aware. Though specific to DNA 17 
methylation, BATMAN, which transforms read densities into absolute methylation 18 
estimates, was recently made CNV-aware by first dividing read densities by copy 19 
number before differential analysis (Feber et al. 2011; Down et al. 2008). However, 20 
this transformation takes measurements off the count scale, which may affect the 21 
sensitivity of subsequent statistical analyses. 22 
We propose a flexible and general statistical framework called ABCD-DNA that 23 
explicitly adjusts for CNV in differential epigenome analyses.  First, we describe the 24 
statistical framework, which necessarily involves considerations for the estimation of 25 
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CNV and normalization.  Second, we illustrate the effects of CNV on various 1 
algorithms for differential analysis across multiple qDNA-seq datasets.  Using 2 
independent truth (DNA methylation levels), we demonstrate improved differential 3 
detection performance using CNV-aware analyses. Third, we compare the 4 
performance of ABCD-DNA and competing methods, demonstrating the proposed 5 
framework is competitive against existing approaches and flexible, irrespective of 6 
CNV compensation. All methods are freely available in public software projects and 7 
R scripts to reproduce all analyses are provided. 8 
RESULTS 9 
A general framework for CNV-aware differential qDNA-seq analyses  10 
We propose the following framework: 11 
1. Generate read counts at regions of interest (e.g. at detected peaks, tiled 12 
regions genome-wide, or proximal to transcription starts); 13 
2. Estimate copy number offsets from an external data source (see “Copy 14 
number analyses” below); 15 
3. Estimate normalization offsets based on CNV-neutral loci (See 16 
“Normalization” below); 17 
4. Perform differential analysis of count data (e.g. using edgeR) using offsets. 18 
Formally, the strategy for CNV-aware differential analyses can be encapsulated in a 19 
generalized linear model (GLM), where tools applicable to genome-scale datasets 20 
have recently become available (McCarthy et al. 2012; Anders and Huber 2010; Zhou 21 
et al. 2011).  Specifically, let Yij be the read count for region of interest i in sample j 22 
(i=1,…,r and j=1,…,n where r is the number of regions and n is the number of 23 
samples).  The read density observed at any genomic region is modified by systematic 24 
effects, such as “effective” sequencing depth, copy number, and underlying biological 25 
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factors of interest, as well as sampling and biological variability.  Offsets impose a 1 
higher or lower expected mean based on the systematic factors, such as copy number 2 
state, depth of sequencing and sampling rates due to the diversity of the library 3 
sequenced; these are estimated in advance and treated as fixed in the downstream 4 
analysis.  We model the logarithm of expected value of Yij as follows:  5 
log(E[Yij ]) =  Oij + BiX 6 
where Oij is an rxn matrix of offsets that match the count matrix, X is an rxk matrix 7 
that captures the experimental design (conditions, covariates) and Bi is a rxk matrix of 8 
region-specific coefficients. Oij can be decomposed into log(CNij) + log(1 Dj) where 9 
CNij is a matrix of offsets for copy number and Dj represents sample-specific offset 10 
vector, both of which can be calculated as suggested above. To make inferences 11 
regarding differential enrichment, hypothesis tests can be formulated (e.g. likelihood 12 
ratio test) on the parameters of interest within the Bi matrix (e.g. cancer versus 13 
normal); tools for this are readily available (e.g. edgeR (Robinson, McCarthy, et al. 14 
2010)).  See Supplementary PDF Document for specification of all the modeling 15 
details (e.g. distributional assumptions, statistical testing). 16 
  17 
ABCD-DNA can use alternative CNV sources; CNV linearly affects qDNA-seq 18 
ABCD-DNA requires pre-processed CNV information to be delivered to a GLM in a 19 
corresponding matrix for regions of interest for each sample; in theory, our approach 20 
is independent of the source of CNV information.  However, in practice, the success 21 
of the CNV adjustment will be determined by the accuracy, resolution and scale of the 22 
CNV estimates, which can vary widely with the platform and preprocessing algorithm 23 
used (Curtis et al. 2009).  Accuracy should be facilitated by smoothing techniques, 24 
such as segmentation (Venkatraman and Olshen 2007) while resolution is ultimately 25 
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determined by probe spacing (microarrays) or depth of sequencing (HTS).  In our 1 
analysis of PrEC and LNCaP cells, we used the PICNIC algorithm on Affymetrix 2 
SNP 6.0 array data, which resulted in integer-valued CNV estimates due to the 3 
homogenous population of the cell lines (Figure 1A).  Supplementary Figure 2 4 
highlights strong concordance between PICNIC CNV estimates and segmented low-5 
coverage genomic sequencing read densities, after adjusting for GC content and 6 
mappability (See Methods).  Therefore, only minor differences in the downstream 7 
differential analysis between the alternative sources of CNV offsets should result 8 
(discussed below).  Another important consideration is the scale of the CNV offsets, 9 
and specifically, the relationship between CNV and DNA-seq read depths; the GLM 10 
model assumes a linear relationship between the offset and expected mean.  11 
Supplementary Figure 3 shows M (log-fold-change adjusting for total depth) versus 12 
A (average-log-read-density) “smear” plots for three qDNA-seq datasets across 13 
PICNIC-defined CNV states, highlighting the increase in M as relative CNV 14 
increases.  Furthermore, approximate linearity is observed for all qDNA-seq datasets 15 
(Figure 2), which supports the assumption made by ABCD-DNA in conveying such 16 
offsets to the GLM model. 17 
 18 
Normalization to “neutral” regions  19 
qDNA-seq read density at any given locus is affected by biological factors, such as 20 
CNV and technical factors, such as total sequencing depth and library diversity.  21 
Therefore, “normalization” is a subtle yet important aspect for allowing accurate 22 
comparison of samples.  When are read densities comparable, up to a scaling factor?  23 
This question has been addressed in the context of RNA-seq data, where not only 24 
expression level, but composition of the library and GC content affects read density 25 
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(Robinson and Oshlack 2010; Hansen et al. 2012).  One popular solution is to use a 1 
scaling factor (i.e. an offset) called trimmed mean of M-values (TMM), which allows 2 
observations to be kept on their original scale (i.e. counts) for statistical modeling. 3 
However, TMM normalization does not explicitly handle CNV or the asymmetry of 4 
changes in enrichment (e.g. DNA methylation has opposing global loss in cancer, and 5 
localized gain at CpG-rich regions). To estimate normalization factors, we focus on 6 
the most prominent “neutral” state.  Typically, this will be genomic regions with 2 7 
copies.  However, as mentioned, most of the LNCaP genome has 4 copies, so we 8 
define neutral as autosomal regions with 2 copies for PrEC and 4 copies for LNCaP 9 
(Figure 1a); this spans approximately 65% of the reference genome.  Figure 3 shows 10 
pairwise comparisons of MBDCap-seq samples using only loci from this neutral state.  11 
Due to the logarithm transform, variability of M decreases as A increases (Robinson 12 
and Oshlack 2010). However, because of differences in composition and global 13 
asymmetry in DNA methylation between samples, the center of the M values does not 14 
necessarily occur at 0.  Assuming there are regions similarly enriched in both 15 
samples, we estimate this bias from “neutral” regions only using the regions of lowest 16 
variability (e.g. median of M-values for A > 99th percentile of A-values; See Figure 3) 17 
and introduce a sample-specific offset into the statistical model to compensate for 18 
expected bias in read densities.  Support for this strategy is given in Supplementary 19 
Figure 4, where normalized data (M-values after adjustment by estimated offsets) for 20 
“neutral” loci genome are shown, stratified by CpG density.  Despite the asymmetry 21 
in DNA methylation, our normalization ensures that the M-value asymptotes are 22 
approximately 0, suggesting that read densities are comparable.  23 
 24 
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Differential calls for various assays and algorithms are positively correlated 1 
with CNV  2 
Figures 1B-E highlighted loci where CNV affected read densities, resulting in false 3 
or missed detections.  To highlight that CNV affects many algorithms genome-wide, 4 
we tested several differential approaches: i) DiffBind coupled with MACS output; ii) 5 
RSEG; iii) ChIPDiff; iv) ABCD-DNA using 500bp tiled genomic bins.  We define 6 
relative rate of peak density (RRPD) as the number of regions detected in LNCaP 7 
divided by the number detected in PrEC, for each CNV state (Figure 4).  Generally, 8 
higher (lower) relative CNV results in more (less) differential region detections, for 9 
all algorithms except ABCD-DNA; this positive correlation is indicative of CNV 10 
alone affecting the differential calls.  Although we do not expect this curve to be 11 
completely flat (e.g. interactions between CNV and epigenetics), ABCD-DNA largely 12 
removes this association.   13 
Furthermore, CNV may impact many cancer datasets and algorithms.  For example, 14 
an independent comparison of the LNCaP and PrEC methylome (Kim et al. 2011) by 15 
running a region detection algorithm and simply overlapping lists is strongly affected 16 
by CNV (Supplementary Figure 5). Similarly, differentially methylated regions 17 
detected by MeDIP-seq in breast cancer cell lines (Ruike et al. 2010) are associated 18 
with CNV, according to their input samples (Supplementary Figure 6). Taken 19 
together, these results suggest that a non-trivial fraction of differential peak detections 20 
could be driven simply by CNV, not changes in relative biological enrichment. 21 
 22 
CNV offsets improve differential detection performance  23 
To illustrate that the CNV and normalization offsets proposed above can improve 24 
differential detection, we use an independent readout of differential methylation on 25 
the same LNCaP and PrEC cells.  Using Illumina HumanMethylation 450k BeadChip 26 
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arrays, DNA methylation estimates at individual CpG sites are summarized as beta 1 
values (See Methods). For comparison with the MBDCap-seq data, beta values are 2 
averaged over technical replicates and regions of interest.  Here, regions of interest 3 
comprise non-overlapping 500bp tiled genomic segments where 450k probes exist. 4 
The averaged beta values are used to label regions as differentially methylated 5 
(change in beta > 0.4), not differentially methylated (change in beta < 0.1) or 6 
indeterminate (0.1-0.4).  GLMs are fitted using the edgeR package with and without 7 
CNV offsets (both use normalization offsets) and ranking of regions is according to 8 
likelihood ratio test P-values.  Other cutoffs for difference in beta values were tested 9 
(data not shown) and the results presented here are representative. 10 
Figure 5 shows ROC curves for symmetrically-chosen truly differentially methylated 11 
regions (See Methods), stratified by copy number state, comparing CNV-aware 12 
(“ABCD-DNA”, using either SNP arrays or genomic sequencing for CNV offsets) 13 
and CNV-unaware GLM strategies (“Naïve”), RSEG and DiffBind (with and without 14 
input subtraction) are also compared (See Methods).  Taken together, these results 15 
highlight several features of our new method: i) gains in performance can be achieved 16 
for non-“neutral” regions; ii) the magnitude of performance gain increases as CNV 17 
increases; iii)  ABCD-DNA performs equally well, regardless of the source of CNV 18 
information (Affymetrix SNP 6.0, low coverage genomic sequencing);  iv) ABCD-19 
DNA outperforms competing methods.  20 
To understand the difference that CNV compensation makes genome-wide to 21 
differential detection calls, Supplementary Figure 6 gives Venn diagrams showing 22 
the overlap of CNV-Aware and Naïve calls (adjusted P-value < .01) by CNV state; as 23 
expected, differential calls in the “neutral” regions are unaffected, while the overlap 24 
degrades significantly as CNV increases.  Furthermore, to highlight how ABCD-DNA 25 
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removes the association between differential detection and CNV, Supplementary 1 
Figure 7 shows differential detection Z-scores with and without CNV adjustment, 2 
stratified by CNV and by “true” 450k differential status used in the ROC 3 
comparisons.  Naïve scores increase predictably with CNV, whereas ABCD-DNA 4 
scores are stable across all CNV states, allowing a better separation of truly 5 
differentially methylated from non-differentially methylated. 6 
Because of the asymmetry in the DNA methylation, ROC comparisons are sensitive 7 
to the CNV adjustments made. Probes on the 450k arrays are biased towards CpG-8 
rich regions and since these regions often gain methylation in cancer, there is a 9 
performance advantage to always increasing the log-fold-change, which can confound 10 
the interpretation of the CNV compensation.  To eliminate this bias, our results above 11 
(Figure 6) used randomly selected truly differentially methylated regions such that 12 
the same number increased and decreased.  However, Supplementary Figure 8 13 
highlights ROC comparison where this symmetry was not ensured; in this situation, 14 
we overstate (understate) performance for lower (higher) relative CNV, as expected. 15 
 16 
ABCD-DNA outperforms CNV-aware BATMAN 17 
Next, we compared ABCD-DNA against the CNV-aware BATMAN for the 18 
differential analysis of MeDIP-seq data.  In the original analysis, read densities were 19 
first pre-processed (divided by CNV, explicitly assuming a direct unit slope 20 
relationship) to adjust for CNV before using BATMAN (Feber et al. 2011).  Their 21 
dataset comprises MeDIP-seq, Affymetrix SNP 6.0 and Illumina HumanMethylation 22 
27k arrays for three pooled populations: i) cancer versus normal (malignant 23 
peripheral nerve sheath tumors versus normal Schwann cells); ii) benign versus 24 
normal (benign neurofibromas versus Schwann cells); and, cancer versus benign.  We 25 
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use the 27k array data as independent “truth” for our performance evaluation (as 1 
above, change in beta > 0.4 defines differentially methylated and change in beta < 0.1 2 
is deemed non-differentially methylated).  We estimated CNV offsets from their 3 
Affymetrix SNP 6.0 data using PICNIC and normalization offsets using CNV-neutral 4 
regions, as above.  Notably, because these are sample mixtures, the CNV estimates 5 
could be non-integer-valued.  Figure 6 shows ROC curves for the 3 comparisons 6 
using 3 differential detection approaches: i) the CNV-aware BATMAN (Down et al. 7 
2008; Feber et al. 2011) (“BATMAN”); ii) count-based analysis with only 8 
normalization offsets (“Naïve”); and, iii) count-based analysis with normalization and 9 
CNV offsets (“ABCD-DNA”).  Overall, these results suggest that two gains in 10 
performance can be made: i) count-based methods outperform CNV-aware BATMAN 11 
on 2 out of 3 comparisons, perhaps suggesting that modeling the data on its count 12 
scale followed by direct comparison of read densities performs well; ii) directly 13 
integrating CNV information gives a performance advantage.  In addition, BATMAN 14 
is specific to methylated DNA capture assays, whereas ABCD-DNA can be applied to 15 
other qDNA-seq assays. 16 
DISCUSSION  17 
CNV affects read densities for various qDNA-seq assays.  For differential 18 
comparisons between cancer and normal epigenomes, results can be both driven and 19 
masked by CNV, thus leading to false positives and reduced power (Figure 1).  20 
Cancer qDNA-seq datasets are on the rise and many will ultimately be affected by 21 
CNV.  We present a straightforward solution that explicitly models CNV in a well-22 
established count-based framework.  Our method, called ABCD-DNA, estimates 23 
CNV and normalization offsets, and includes them directly in a GLM, similar to 24 
recent approaches applied to RNA sequencing data (Hansen et al. 2012).  Thus, we 25 
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enable a strategy that jointly accounts for effective sequencing depth and CNV, within 1 
statistical models that handle biological replication.  We verified the approximately 2 
linear relationship between CNV and qDNA-seq on multiple cell line datasets, 3 
suggesting that offsets are presented on an appropriate scale to modify the mean 4 
response.   5 
Using an independent readout of DNA methylation on 2 datasets, we demonstrated 6 
that ABCD-DNA is competitive against existing differential approaches and 7 
integrating CNV through offsets can further improve performance.  In addition, the 8 
ABCD-DNA framework is flexible and extensible.  Because a matrix of offsets is 9 
matched to the matrix of read densities, there is a facility for analyzing datasets with 10 
sample-specific, possibly non-integer, copy number.  For example, patient studies, 11 
where each has a different copy number profile, could be analyzed.  Furthermore, 12 
through the offset matrix, the method can adjust for not only CNV and effective 13 
sequencing depth, but other technical factors that affect read density, such as GC 14 
content or antibody efficiency (Egelhofer et al. 2011; Cheung et al. 2011; Hansen et 15 
al. 2012); further study is required to adequately demonstrate this capability for 16 
qDNA-seq datasets.  Meanwhile, ABCD-DNA can handle replication and 17 
complicated experimental designs, since these are already features of the employed 18 
model (McCarthy et al. 2012).  In principle, ABCD-DNA can make use of any 19 
accurate source of CNV information; however, the success of the CNV adjustment is 20 
ultimately reliant on the accuracy, resolution and scale of these estimates.  21 
Furthermore and perhaps most importantly, ABCD-DNA can be applied to 22 
differential analysis of various qDNA-seq datasets, including ChIP-seq.   23 
One potential disadvantage of our approach is the reliance on regions of interest, such 24 
as regions tiled along the genome; the positioning of these regions could have some 25 
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effect.  An alternative strategy would be to consider overlapping bins tiled at high 1 
density, in combination with principled techniques for smoothing, such as HMMs, to 2 
assemble differential regions; this work is beyond the scope of the proof-of-principle 3 
presented here.  In addition, ABCD-DNA does not currently have a facility for 4 
incorporating “input” or control samples; on our evaluation dataset, DiffBind’s 5 
explicit input subtraction did not convincingly improve performance and other reports 6 
have challenged the appropriateness of such controls (Cheung et al. 2011).  Further 7 
study is required to make general recommendations on this matter. 8 
The main implication of our results is that CNV information, at least for cancer 9 
studies, is required for interpretation of qDNA-seq read densities. Failing to account 10 
for CNV may result in false positives and false negatives (e.g. Figure 1B-E) and 11 
could have significant impact on downstream analyses.  For example, if CNV is 12 
responsible for a significant fraction of naively determined differentially enriched 13 
regions, downstream analyses, such as functional category analysis or pathway 14 
analysis, may be confounded by CNV; that is, enriched pathways may largely be a 15 
reflection of CNV, not from changes in the epigenetic factor of interest.  Since 16 
ABCD-DNA adjusts expected read density by number of copies, the method can also 17 
facilitate detection of changes in allele-specificity; however, partitioning the reads by 18 
allele using genotypes is a more direct approach for this (Statham et al. 2012). 19 
Unfortunately, the requirement for CNV information imposes a potentially costly 20 
burden for researchers studying cancer epigenomes, since every sample will need to 21 
CNV-typed; this would consume sequencing resources and precious DNA.  In 22 
practice, the effect of CNV on qDNA-seq can be large or small, depending on the 23 
type and severity of the cancers being studied.  In the comparison of LNCaP and 24 
PrEC cells, the magnitude of CNV change is moderate (most often, changes from 4 25 
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copies to 3 or 5), but a large proportion of the genome (~35%) is affected, so 1 
significant improvements can be made.  Depending on the cancer and the severity, 2 
copy number aberrations may be larger in magnitude than our dataset, and affect 3 
larger (or smaller) proportions of the genome (Baudis and Cleary 2001).  So, the gains 4 
to be made from CNV-aware analyses are dataset-dependent.  However, from our 5 
initial results, there is generally only gains to be made after integrating CNV.  6 
Furthermore, while the main motivation to develop ABCD-DNA is to compensate for 7 
CNV, we have shown that it performs well relative to existing approaches, so the 8 
framework may benefit differential qDNA-seq analyses outside of the cancer field. 9 
 10 
METHODS 11 
Estimating CNV from Affymetrix SNP 6.0 microarrays  12 
The PICNIC tool (Greenman et al. 2010), specifically designed for the analysis of 13 
Affymetrix SNP 6.0 arrays, was used to estimate absolute copy number genome-wide 14 
using default parameters.  These regional estimates were matched to the read densities 15 
in tiled bins along the genome and used directly as offsets in the downstream CNV-16 
aware GLM count modeling. 17 
 18 
Estimating CNV from genomic sequencing  19 
Since read depths in genomic DNA sequencing are affected by local GC content and 20 
mappability, we implemented a R routine in the Repitools package (Statham et al. 21 
2010) called absoluteCN() that calculates read density, GC content and 22 
mappability in bins genome-wide.  Bins with mappability less than 75% are removed; 23 
a smooth curve is fit to the mode of depth versus GC content.  This relationship is 24 
removed for each bin by dividing out the fit at the bin’s GC content and then scaled 25 
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according to knowledge of the most prominent copy state (here, LNCaP=4 and 1 
PrEC=2).  Read densities are then segmented using CBS (Venkatraman and Olshen 2 
2007). 3 
Choosing regions for ROC analysis “symmetrically” 4 
Because the truly differentially methylated regions for the LNCaP versus PrEC 5 
comparison are biased towards hypermethylation, we randomly selected the same 6 
number of truly hypermethylated and truly hypomethylated regions for the ROC 7 
analysis.  8 
ROC analysis using RSEG 9 
To generate ROC curves for RSEG, we ran rseg-diff repeatedly with different 10 
values of the -cdf-cutoff parameter (between 0.01 and 0.40).  For each of the 11 
truly differentially methylated and non-differentially methylated regions, the score 12 
used for ROC analysis was the maximum cdf-cutoff such that the region was deemed 13 
differentially enriched, if at all.  See Supplementary website describing the commands 14 
used for each tool. 15 
ROC analysis using DiffBind 16 
To generate ROC curves for DiffBind, we set a high P-value threshold when calling 17 
dba.report(), thus giving scores for the full list of inputted regions.  The score 18 
used for ranking was the P-value.  Furthermore, whether to subtract input reads was 19 
controlled by the bSubControl=FALSE argument in the call to 20 
dba.analyze().  Otherwise, default parameters were used. 21 
Processing of Illumina HumanMethylation 450k array data 22 
The HumanMethylation 450k arrays were processed using the R/Bioconductor ‘minfi’ 23 
package using bg.correct = TRUE and normalize = "controls", to 24 
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generate beta values.  Differences in beta values were used to determine the truly 1 
differentially methylated regions. 2 
Reproducibility of analyses and figures in this manuscript 3 
All data and R code used for the generation of figures in this manuscript are available 4 
from <http://imlspenticton.uzh.ch/robinson_lab/ABCD-DNA/> with further 5 
description in the Sweave-based Supplementary PDF Document.   6 
 7 
DATA ACCESS 8 
Datasets used 9 
The following datasets (with NCBI Gene Expression Omnibus accession numbers) 10 
were used for the main comparisons: 11 
1. MBDCap-seq, Affymetrix SNP 6.0 arrays, and low coverage genomic DNA 12 
sequencing on LNCaP and PrEC cells and MBDCap-seq of SssI (fully 13 
methylated DNA) (GSE24546) (Robinson, Clare Stirzaker, et al. 2010), as 14 
well as H3K27me3-seq (GSE38683) and H3K4me3-seq (GSE38682) on the 15 
same cell lines. 16 
2. Illumina HumanMethylation 450k bead array on LNCaP and PrEC 17 
(GSE34340) 18 
3. From Feber et al. study (Feber et al. 2011), MeDIP-seq, Affymetrix SNP 6.0 19 
arrays and Illumina HumanMethylation 27k were available for pools of 20 
malignant peripheral nerve sheath tumors, normal Schwann and benign 21 
neurofibromas. 22 
Additional analyses to investigate the association between CNV and differential 23 
region detection:  24 
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1. Ruike MeDIP-seq and input-seq data (Ruike et al. 2010): reads were 1 
downloaded from the DDBJ Sequence Read Archive (accession DRP000030) 2 
and remapped to the human hg18 genome.  A list of differential regions was 3 
obtained from Yoshinao Ruike (personal communication); analysis of the 4 
association between their corresponding input-seq read densities and detected 5 
differential regions was performed using a custom R script. 6 
2. Kim et al. M-NGS data (Kim et al. 2011):  The list of differentially methylated 7 
regions was obtained from Mohan Dhanasekaran (personal communication); 8 
using our SNP array data (same cell lines), associations were made to their 9 
detected regions using a custom R script. 10 
Reproducibility of analyses and figures in this manuscript 11 
All data and R code used for generating figures in this manuscript are available from 12 
http://imlspenticton.uzh.ch/robinson_lab/ABCD-DNA/. 13 
Software to run ABCD-DNA 14 
A detailed description of the implementation details for ABCD-DNA is given in the 15 
Supplementary PDF Document.  Software to run ABCD-DNA is freely available 16 
within the Bioconductor Repitools package (Statham et al. 2010). 17 
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FIGURE LEGENDS 1 
Figure 1. CNV causes false positives and false negatives to various algorithms; 2 
ABCD-DNA can recover them. A) The landscape of CNV between LNCaP (black) 3 
and PrEC (grey) cells inferred by PICNIC algorithm (using Affymetrix SNP 6.0 data, 4 
see Methods). Using Illumina 450k array data to gauge true differential methylation 5 
(See tracks “LNCaP 450k” and “PrEC 450k”), four CNV-induced false positive (FP) 6 
or false negative (FN) regions in MBDCap-seq data (See tracks “LNCaP_MBD2” and 7 
“PrEC_MBD2”) using existing algorithms are shown.  Detected differential regions 8 
for four methods (ChIPDiff, DiffBind, RSEG, our new approach ABCD-DNA) are 9 
shown in black. Region B) shows a FN for all algorithms except ABCD-DNA; the 10 
change in depth-normalized read density is not particularly strong, but combined with 11 
the knowledge that this is a “low” copy region (LNCaP=2), ABCD-DNA expects 12 
fewer reads.  Hence, the effective difference is made larger and therefore deemed 13 
differential by ABCD-DNA.  Similarly, region C) is amplified in cancer beyond 14 
“neutral” (LNCaP=5), thus ABCD-DNA expects higher read density (if methylated) 15 
and correctly increases the effective change.  Region D) is similarly amplified, which 16 
causes existing algorithms to overstate the differential methylation (i.e. a FP); note the 17 
upstream differentially methylated region that all algorithms detect, whereas only 18 
ABCD-DNA correctly attributes the downstream change in read density to CNV.  19 
Region E) is lower copy in LNCaP cells, resulting in lower read depth and FPs for all 20 
methods except ABCD-DNA. 21 
 22 
Figure 2. Linearity between CNV and qDNA-seq. Relative read densities scale 23 
linearly with CNV for multiple LNCaP/PrEC qDNA-seq (MBDCap, H3K27me3, 24 
H3K4me3) datasets.  Scaling factors were calculated separately as the median of log-25 
fold-changes (median of M values) for each CNV stratum and each dataset (See 26 
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Supplementary Figure 3); these medians were exponentiated and scaled according to 1 
the most prominent CNV state (L=4 P=2).  Note that these scaling factors are not 2 
actually used in the ABCD-DNA method; they are shown here only to illustrate the 3 
relationship between qDNA-seq and CNV. 4 
 5 
Figure 3. Normalization to “neutral” CNV state using estimated scaling factors.  6 
M (depth-normalized log-fold-change) versus A (depth-normalized average-log) 7 
“smear” plots for MBDCap-seq data are shown between technical replicates (A) and 8 
between cancer and normal (B); each dot represents a 500bp region of the genome.  M 9 
is defined as the log-fold-change between 2 samples (counts divided by library size); 10 
A is average of the log counts divided by library size.  Blue lines represent 99th 11 
percentile of A values; red lines denote scale factor estimates (median of M for 12 
regions with A greater than 99th percentile).  Note: these scale factors are presented 13 
here 14 
 15 
Figure 4.  Association between differential peak detection and CNV across 16 
LNCaP/PrEC qDNA-seq datasets using various algorithms.  The relative rate of 17 
peak detection (RRPD), defined as the ratio of the number of regions detected in 18 
LNCaP (L) cells to the number of regions detected in PrEC (P), within each CNV 19 
stratum is shown for ChIPDiff, RSEG, DiffBind (with and without input subtraction) 20 
and ABCD-DNA.  DiffBind is based on MACS-detected regions. A) MBDCap-seq; 21 
B) H3K27me3-seq; C) H3K4me3-seq.  Due to lack of replication, DiffBind was not 22 
run on H3K4me3-seq. 23 
 24 
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Figure 5.  ABCD-DNA outperforms competing approaches. ROC curves 1 
(sensitivity versus 1-specificity) are shown for various differential region detection 2 
algorithms operating on MBDCap-seq data, using 450k array data as an independent 3 
source of truly and non-truly differentially methylated regions.  “Naïve” uses offsets 4 
to account for (effective) sequencing depth but not CNV; “ABCD-DNA” uses either 5 
Affymetrix SNP 6.0 or genomic sequencing to estimate CNV offsets. “RSEG” 6 
denotes running rseg-diff with different sensitivity cutoffs.  “DiffBind”, which 7 
operates on MACS-detected regions, was run both with and without input subtraction. 8 
Each panel shows ROC curves for the respective CNV stratum (between LNCaP and 9 
PrEC cells), as indicated in the panel title; the number of such regions is shown in 10 
parentheses.  In the “L=4 P=2” panel, Naïve and both ABCD-DNA curves almost 11 
completely overlap, as do the two DiffBind curves (with and without input 12 
subtraction). 13 
 14 
Figure 6. ABCD-DNA outperforms CNV-aware BATMAN.  ROC curves 15 
(sensitivity versus 1-specificity) for 3 pairwise comparisons are shown for a MeDIP-16 
seq dataset (Feber et al. 2011), where Illumina HumanMethylation 27k data is used as 17 
an independent source of truly and non-truly differentially methylated regions.  18 
“BATMAN” refers to the CNV-adjusted read densities before running the BATMAN 19 
algorithm and taking differences in methylation estimates.  “Naïve” refers to a count-20 
based analysis, without accounting for CNV.  “ABCD-DNA” refers to a count-based 21 
analysis, with additional offsets to account for CNV (estimated from Affymetrix SNP 22 
6.0 data using the PICNIC algorithm).  Comparisons are: A) cancer versus normal; B) 23 
cancer versus benign; C) benign versus normal.  24 
 25 
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TABLES 1 
Table 1. Table of acronyms for relevant assays and tools.   2 
 3 
Acronym Description Reference 
MBDCap Methyl-binding domain based capture - 
qDNA-seq Sequencing of captured DNA 
subpopulations (i.e. quantitative) 
- 
GLM Generalized linear model (McCarthy et al. 2012) 
RSEG Identifying dispersed epigenomic domains 
from ChIP-Seq data 
 
(Qiang Song and Smith 
2011) 
ZINBA Zero-Inflated Negative Binomial 
Algorithm 
(Rashid et al. 2011) 
DiffBind Differential Binding Analysis of ChIP-Seq 
peak data 
(Ross-Innes et al. 2012) 
DBChip Detecting differential binding of 
transcription factors with ChIP-seq 
 
(Liang and Keles 2011) 
BATMAN A Bayesian Tool for Methylation Analysis 
 
(Down et al. 2008; Feber 
et al. 2011) 
PICNIC  Predict integral copy numbers in cancer 
 
(Greenman et al. 2010) 
 4 
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